FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
Publishing timestamp: 2024-06-07 18:21:42
Summary
The FDA expanded approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59, helping the company maintain its dominance in the RSV market. The vaccine, called Arexvy, is the first to be cleared by the FDA for this age group, who are at increased risk of severe illness from RSV. GSK is confident in the vaccine's potential for peak annual sales and is also studying its efficacy in other patient groups and in other countries.
Sentiment: POSITIVE
Tickers: GSK, PFE, GSK-GB, MRNA,
Keywords: gsk plc, breaking news, business, moderna inc, pfizer inc, biotechnology, pharmaceuticals, biotech and pharmaceuticals, business news, vaccinations, science, respiratory syncytial virus, health care industry,
Source: https://www.cnbc.com/2024/06/07/fda-approves-gsk-rsv-vaccine-for-adults-50-to-59.html